CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 254 filers reported holding CLOVIS ONCOLOGY INC in Q4 2017. The put-call ratio across all filers is 0.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2018 | $2,421,000 | +309.6% | 82,430 | +534.1% | 5.78% | +350.9% |
Q2 2018 | $591,000 | -13.8% | 13,000 | 0.0% | 1.28% | -4.7% |
Q1 2018 | $686,000 | -32.7% | 13,000 | -13.3% | 1.34% | +52.5% |
Q4 2017 | $1,020,000 | -17.5% | 15,000 | 0.0% | 0.88% | -20.5% |
Q3 2017 | $1,236,000 | -12.0% | 15,000 | 0.0% | 1.11% | -13.8% |
Q2 2017 | $1,404,000 | -26.5% | 15,000 | -50.0% | 1.29% | -9.3% |
Q1 2017 | $1,910,000 | +43.3% | 30,000 | 0.0% | 1.42% | +33.5% |
Q4 2016 | $1,333,000 | -7.4% | 30,000 | -60.0% | 1.06% | -4.6% |
Q1 2016 | $1,440,000 | -17.7% | 75,000 | +50.0% | 1.11% | -3.7% |
Q4 2015 | $1,750,000 | -67.5% | 50,000 | -14.6% | 1.16% | -61.1% |
Q3 2015 | $5,386,000 | +17.0% | 58,567 | +11.8% | 2.97% | -18.5% |
Q2 2015 | $4,605,000 | +10.8% | 52,400 | -6.4% | 3.65% | +4.7% |
Q1 2015 | $4,156,000 | +174.9% | 55,988 | +107.4% | 3.48% | +132.8% |
Q4 2014 | $1,512,000 | – | 27,000 | – | 1.50% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 814,833 | $45,630,648,000 | 43.63% |
EcoR1 Capital, LLC | 384,348 | $21,523,000 | 10.89% |
Palo Alto Investors LP | 2,102,857 | $117,760,000 | 6.91% |
NEA Management Company, LLC | 2,279,781 | $127,668,000 | 6.19% |
Redmile Group, LLC | 721,632 | $40,411,000 | 4.40% |
Opaleye Management Inc. | 140,000 | $7,840,000 | 3.96% |
CLIFTON PARK CAPITAL MANAGEMENT, LLC | 790,555 | $44,271,000 | 2.63% |
SUFFOLK CAPITAL MANAGEMENT LLC | 339,327 | $19,002,000 | 2.31% |
PFM Health Sciences, LP | 1,725,126 | $96,607,000 | 2.26% |
HARBOURVEST PARTNERS LLC | 51,037 | $2,858,000 | 1.50% |